摘要
目的:探讨比卡鲁胺联合戈舍瑞林不同给药方式治疗晚期前列腺癌的治疗效果及安全性。方法:将2015年1月—2017年8月我院收治的62例晚期前列腺癌患者采用随机数字表法分为对照组和观察组,各31例。对照组采取持续性给药(口服比卡鲁胺50 mg,qd;皮下注射戈舍瑞林3.6 mg,1次/4w),观察组实施间歇给药(PSA≤0.2 ng/mL时停用,当PSA>4 ng/mL时继续使用),两组用量用法相同,疗程为1年。比较两组治疗前后血清前列腺特异性抗原(PSA)、临床疗效及不良反应发生情况。结果:两组治疗后3,6,9,12个月的PSA水平均低于治疗前,差异有统计学意义(P<0.05),但组间比较差异无统计学意义(P>0.05);治疗后观察组总缓解率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P<0.05)。结论:比卡鲁胺联合戈舍瑞林的两种给药方式均能明显降低晚期前列腺癌患者的血清PSA,而间歇性给药的临床疗效明显优于持续性给药,且安全性好。
Objective:To investigate the efficacy and safety of different administration modes of bicalutamide combined with goserelin in the treatment of advanced prostate cancer.Methods:62 patients with advanced prostate cancer admitted to our hospital from January 2015 to August 2017 were randomly divided into a control group and an observation group,31 cases each.The patients in the control group received continuous administration(oral administration of bicalutamide 50 mg,qd;subcutaneous injection of goserelin 3.6 mg once/4 w),and the patients in the observation group were administered intermittently(stopping administration when PSA was≤0.2 ng/mL,continuing administration when PSA was>4 ng/mL).The dosage of the two groups was the same,and the course of treatment was 1 year.The serum prostate specific antigen(PSA)before and after treatment,clinical efficacy and adverse reactions were compared between the two groups.Results:The PSA levels at 3,6,9 and 12 months after treatment were lower than those before treatment in the treatment,and the differences were statistically significant(P<0.05),but the difference between the groups was not statistically significant(P>0.05).After treatment,the total remission rate in the observation group was higher than that in the control group,with statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The two administration modes of bicalutamide combined with goserelin can significantly reduce serum PSA in the patients with advanced prostate cancer,while the intermittent administration has better clinical effect than the continuous administration,and has good safety.
作者
胡祥
Hu Xiang(Department of Urology,General Hospital of Yimei Group,Yima Henan 472300,China)
出处
《中国合理用药探索》
CAS
2019年第10期61-63,66,共4页
Chinese Journal of Rational Drug Use
关键词
比卡鲁胺
戈舍瑞林
晚期前列腺癌
持续性
间歇性
Bicalutamide
Goserelin
Advanced Prostate Cancer
Continuous
Intermittent
作者简介
胡祥,男,主治医师。研究方向:前列腺癌内分泌治疗。E-mail:113692478@qq.com
